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Cyclooxygenase-2 promotes tumor 
growth and suppresses tumor immunity
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Abstract 
Cyclooxygenase-2 (COX-2), an inducible form of the enzyme that catalyzes the first step in the synthesis of pros-
tanoids, is associated with inflammatory diseases and carcinogenesis, which is suspected to promote angiogenesis 
and tissue invasion of tumors and resistance to apoptosis. Meanwhile, COX-2 contributes to immune evasion and 
resistance to cancer immunotherapy, which plays a crucial role in the innate and adaptive immune response. The 
activity of COX-2-PGE2-EP signal pathway can suppress Dendritic cells (DCs), natural killer (NK), T cells, type-1 immu-
nity excluding type-2 immunity which promote tumor immune evasion. COX-2 and the prostaglandin cascade play 
important roles in the “inflammogenesis of cancer”. In addition, COX-inhibitors can inhibit tumor immune evasion. 
Therefore, we can exert the COX-inhibitors to facilitate the patients to benefit from addition of COX-inhibitors to 
standard cytotoxic therapy.
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Background
Human malignancies generally arise as the culmination 
of a multistep process that involves various somatic gene 
alterations. Therefore, we can exert the drug to affect 
over-expressed or low-expressed genes and achieve the 
therapies of human malignancies. It was learned that 
COX-2 is overexpressed in most solid tumors such as 
colorectal, liver, pancreatic, breast as well as lung can-
cer [1–6]. Both non-selective non-steroidal anti-inflam-
matory drugs (NSAIDs) and selective COX-2 inhibitors 
can inhibit proliferation, tumors invasiveness and angio-
genesis, and at the same time overcome apoptosis and 
drug resistance as well as suppress of immune responses. 
Immune responses include innate immunity and adap-
tive immunity. Tumor-associated immune responses can 
be generalized to type 1, in which Th1 lymphocytes and 
M1-polarized macrophages limit tumor progression, and 
type 2, in which Th2 lymphocytes and M2 macrophages 
favor immune escape and disease progression [7]. Natu-
ral Killer (NK) cells are a subset of lymphocytes that 
participate in innate immunity. Dendritic cells bridge 
innate and adaptive immunity and participate in both 
responses. Tumor-associated macrophages (TAMs) have 
emerged as promising target for anti-cancer immuno-
therapy. MDSC block adaptive immunity. Cytotoxic T 
cells directed against antigens that are endogenously 
expressed and presented by cancer cells are critically 
involved in antigen-specific cancer immunotherapy.
Meanwhile, COX-2 contributes to immune evasion 
and resistance to cancer immunotherapy. The activ-
ity of COX-2 -PGE2-EPs signal pathway can suppress 
Dendritic cells (DCs), natural killer (NK), T cells, type-1 
immunity, but promote type-2 immunity, which pro-
mote tumor immune evasion. COX-2 inhibitors may 
have off-target effects on immune cells and can coun-
terbalance their activity as enhancers of susceptibility to 
immune elimination. So, COX-2 may serve as predictive 
biomarker and as therapeutic target for modulation of 
immune resistance in cancer.
Cyclooxygenase
The cyclooxygenase (COX) isoenzymes, known as pros-
taglandin (PG) rate-limiting synthase, catalyze the 
metabolism of arachidonic acid (AA) to PGs. Finally, a 
series of biologically active prostaglandins (PGD2, PGE2, 
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PGF2α, and PGI2) and thromboxane A2 (TXA2) are 
formed. There are three isoforms of the enzyme that have 
been identified: COX-1, COX-2, and COX-3 [8]. Consid-
ered as a “housekeeping enzyme”, COX-1 is constitutively 
expressed in human cells. COX-3, an alternate splice var-
iant of COX-1, is most abundant in the canine cerebral 
cortex. COX-2 is an inducible enzyme and is associated 
with inflammatory diseases and carcinogenesis, which 
is suspected to promote angiogenesis and tissue inva-
sion of tumors [9, 10] and resistance to apoptosis [8, 11]. 
Moreover, COX-2-dependent prostaglandin release can 
suppress antigen presentation and immune activation 
in cancer [12]. Therefore, COX-2 and the prostaglandin 
cascade play important roles in the “inflammogenesis of 
cancer”.
COX‑2: PGE2‑prostaglandin E receptors signal 
pathway
Arachidonic acid (AA) is transformed into unstable inter-
mediate PGG2, which is promptly converted into PGH2 
by cyclooxygenases (COXs) and finally into five primary 
prostaglandins (PGD2, PGE2, PGF2α, PGI2, and TXA2) by 
cell-specific synthases. The actions of these prostanoid 
ligands are mediated by their engagement of specific cell-
surface G-protein-coupled receptors designated EP1–4 
for PGE2 [13]. It is widely accepted that alterations of 
cyclooxygenase-2 (COX-2) expression as well as its mas-
sive enzymatic product PGE2 play a key role in influ-
encing the development of cancer because their level is 
found markedly elevated in tissues of cancer [1–6].
Both COX-1 and COX-2 are capable of converting AA 
into prostaglandins. However, they exhibit preferentially 
in synthesizing prostaglandins [14]. It has been demon-
strated that PGE2 and PGI2 are mainly derived from the 
COX-2 pathway [15]. PGE2 is generated from PGH2 by 
cytosolic PGE2 synthase (cPGES) and membrane-bound 
microsomal PGE2 synthase-1 and -2 (mPGEs-1 and -2). 
Once PGE2 is synthesized, it diffuses immediately and 
activates its specific membrane receptors (EP1–4). EP1 
receptors couple with the Gq-phospholipase C(PLC)-
inositol trisphosphate (IP3) pathway and its activation 
results in the release of intracellular Ca2+. EP2 and EP4 
receptors couple with the Gs-adenylyl cyclase (AC)-
cAMP-protein kinase A (PKA) pathway. EP3 couples 
with a pertussis toxin-sensitive Gi protein to inhibit AC 
resulting in a decrease in cAMP [15].
Chell et  al. [16] report that compared with normal 
colonic epithelium, protein expression will increased in 
colorectal cancers (100  %) as well as adenomas (36  %) 
when using immunohistochemistry in vivo EP4 receptor. 
PGE2 signaling through the EP4 receptor has previously 
been associated with colorectal tumorigenesis. Fujino H 
reported that EP2 receptor mediated activation of Tcf 
transcriptional activity is primarily through a cAMP/
protein kinase A (PKA) dependent mechanism; whereas, 
EP4 receptor mediated activation occurs primarily 
through a phosphatidylinositol 3-kinase (PI3K) depend-
ent pathway [17]. Recently, they have found that PGE2 
stimulation of EP4 receptors activates an additional 
PI3K-dependent pathway leading to the phosphoryla-
tion of the extracellular signal-regulated kinases (ERKs), 
followed by induction of the functional expression of 
early growth response factor 1 (EGR-1) [18, 19]. ERKs 
phosphorylation and induction of EGR-1 expression was 
unique for EP4 receptors and was not observed in cells 
that expressed EP2 receptors [18, 19]. Cyclin D1, a key 
regulator of cell cycle progression, is under the control 
of EGR-1 through a PI3K- and ERK-dependent pathway 
[20]. EP4-dependent activation of PI3K/Akt signaling has 
been reported to stimulate the proliferation and motil-
ity of colorectal cancer cells [21]. Therefore, it concerns a 
possible role for EP4 receptors in cancer.
The role which EP2 receptors played in cancer is still 
controversial. Sonoshita et al. [22] showed that homozy-
gous deletion of the gene encoding EP2 would cause 
the decreases in number and size of intestinal polyps 
in ApcΔ716 mice (a mouse model for human familial 
adenomatous polyposis). Homozygous gene knockout 
for other PGE2 receptors, EP1 or EP3, did not affect the 
intestinal polyp formation in ApcΔ716 mice. Fujino et al. 
[17] suggested that the increased expression of COX-2 
via EP2 receptors and an increased expression of PGE2 
synthase via EP4 receptors could explain the increased 
biosynthesis of PGE2 known to occur in colon cancer.
COX‑2: PGE2‑prostaglandin E receptors suppress 
innate and adaptive immunity
COX-2: PGE2-prostaglandin E receptors contributes 
to immune evasion and resistance to cancer immuno-
therapy (Table 1), which have been reported to augment 
pro-tumorigenic type 2 lymphocyte [23]. COX-2: PGE2 
has been considered as a major product and modulator 
of activated macrophages [24] for a long time. Tumor-
associated macrophages (TAMs) represent a major sub-
population of tumor infiltrating immune cells, which has 
emerged as a promising target for anti-cancer immuno-
therapy. Hindering macrophage polarization towards a 
pro-tumor M2 phenotype, or better still reprogramming 
the M2 like TAMs towards M1 subtype is being consid-
ered a beneficial anti-cancer strategy. COX-2/PGE2 Path-
way Promotes M2 Macrophage Differentiation [25, 26]. 
Macrophage-mediated immune suppression is correlated 
with increased CD4+  CD25+  regulatory T cell infiltra-
tion and reduced CD8+ cytotoxic T cell function.
Natural Killer (NK) cells are a subset of lymphocytes 
that participate in innate immunity. NK cells express all 
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PGE2 EP receptors, and tumor-derived PGE2 represents 
a major barrier to the success of NK cell mediated killing. 
PGE2 inhibits the potential of NK cells to migrate, exert 
cytotoxic effects, and secrete interferonγ [27]. Martinet 
et al. [28] also demonstrate that the major NK receptors 
(NKR): NKG2D, CD16 and natural cytotoxicity receptors 
(NCR: NKp30, NKp44, NKp46) are all inhibited by PGE2. 
The ability of PGE2 to inhibit NK cells is by acting on 
EP2 and EP4 receptors. They also report that a recently 
described EP4 antagonist, frondoside A, inhibits breast 
tumor metastasis in an NK-dependent manner and pro-
tects IFNγ production by NK cells from PGE2 mediated 
suppression.
Dendritic cells could bridge the innate and adaptive 
immunity and participate in both responses. COX-2/
PGE2 has become a key immunomodulator of DC biol-
ogy [29], which can exert inhibitory activity and reduce 
the maturation of DCs and their expression of MHC 
class II molecules, ability to present antigen and activate 
T cells [30]. Meanwhile, prostaglandin E2 enhances the 
production of endogenous IL-10, which down-regulates 
dendritic cell functions. PGE2 modulates dendritic cell 
function via EP2 and EP4 receptor subtypes. It is sug-
gested that targeting PGE2 EP2/EP4 receptor signaling 
may be a powerful mechanism for modulating DC activ-
ity [31].
Over-expression of COX-2 can initiate and promote 
carcinogenesis by inhibiting proliferation of B and T lym-
phocytes, particularly natural killer T cells, thus limiting 
antineoplastic activity (immunosuppression) [32]. Göbel 
et  al. [33] have identified COX-2—PGE2 as resistance 
factor against the cytotoxicity induced by activated, anti-
gen-specific T cells. COX-2 expression blunted the inter-
feron-gamma release of antigen-specific T cells exposed 
to their respective cellular targets, and increased the 
expression of interleukin-4 and indoleamine 2,3-dioxyge-
nase by tumor cells.
It has been reported that γδ T cell receptors TCR 
Vγ9Vδ2, NKG2D and CD16 are all inhibited by PGE2 
[28]. PGE2 also contributes to inhibit directly the pro-
liferation and effector functions of CD4+ and CD8+ T 
cells and to promote their differentiation in regulatory T 
cells [34]. COX-2/PGE(2) induces Tregs, and Treg cells 
support the cancer-mediated immune suppression. The 
extent of COX-2 expression was associated significantly 
with Treg prevalence (P = 0.004) and Treg intratumoral 
localization (P = 0.005) [35]. Several studies have demon-
strated that Treg cells contribute to immunosuppression 
Table 1 The role of COX‑2 as an oncogene or suppression of tumor immunity
Oncogene Promotes angiogenesis and tissue invasion of tumors [7, 8], resistance to apoptosis [9, 10]
COX-2-PGE2-Prostaglandin E Receptors signal pathway [12]
PI3K-dependent pathway [16]
Extracellular signal-regulated kinases (ERKs) [17]
Early growth response factor 1 (EGR-1) [18]
Innate immunity
 Macrophages Augment pro-tumorigenic type 2 lymphocyte [22]
Promotes M2 macrophage differentiation [24, 25]
 Natural Killer (NK) cells  Inhibits the potential of NK cells to migrate, exert cytotoxic effects, and secrete interferonγ [26]
Inhibits major NK receptors (NKR): NKG2D, CD16 and natural cytotoxicity receptors (NCR: NKp30, 
NKp44, NKp46) [27]
 Dendritic cells A key immunomodulator of DC biology [28]
Reduces the maturation of DCs and their expression of MHC class II
molecules [29]
The production of endogenous IL-10 adaptive immunity
Adaptive immunity
 B and T cells Inhibits proliferation of B and T lymphocytes [31]
Bluntes the interferon-gamma release of antigen-specific T cells and increased the expression of 
interleukin-4 and indoleamine
2,3-dioxygenase by tumor cells [32]
 γδ T cells Inhibits γδ T cell receptors TCR Vγ9Vδ2, NKG2D, CD16 [27]
 Tregs Induces Tregs [34]
Promotes CD4+ and CD8+ T cells differentiation in Tregs [33]
Inhibits effector T cells in a COX-2-dependent manner [35, 36]
 MDSC COX-2 would maintain elevated MDSC levels [40]
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in cancer and inhibit effector T cells in a COX-2-depend-
ent manner [36, 37]. The suppressive activity of T regula-
tory cells is driven by expression of the forkhead/winged 
helix transcription factor (FOXP3) gene [38, 39].
MDSC are present in many cancers, which block adap-
tive immunity by inhibiting the activation of CD4+ and 
CD8+ T cells [40] and innate immunity by inhibiting nat-
ural killer cells [41].Once a tumor is established, tumor 
cell production of COX2 would maintain elevated MDSC 
levels, further blocking tumor immunity and allowing the 
malignant cells to proliferate without interference from 
the host’s immune system. This provides a rationale for 
therapeutic targeting of COX-2 expression and stress-
induced prostaglandin synthesis to boost immune sur-
veillance and immunotherapy of cancer.
Above all, COX-2—PGE2- EP2/4 signal pathway plays 
an important part in the development of cancer; there-
fore, the EP2/4 receptors may represent an important 
target for cancer prevention and treatment.
COX‑2 inhibitors inhibit immune evasion
Conventional non-steroidal anti-inflammatory drugs 
(NSAIDs) and COX-2 selective inhibitors have been 
demonstrated to overcome tumor immune evasion. It 
has been suggested that COX-inhibitors may sensitize 
type 1 immune responses via inhibiting M2 macrophage, 
T regulatory cells, MDSC; enhancing DC, NK, cytotoxic 
T-lymphocyte functions [42]. Use of selective COX-2 
inhibitors could result in a significant risk reduction 
for each type of cancer (71 % for breast cancer, 55 % for 
prostate cancer, 70 % for colon cancer, and 79 % for lung 
cancer) and an overall 68  % risk reduction for all four 
cancers. This investigation demonstrates that COX-2 
blocking agents have strong potential for the chemopre-
vention of cancers [32].
PGE2 inhibits production of the inflammatory 
chemokines CCL3 and CCL4, which is mediated through 
EP2 and EP4 receptors, preventing excess accumulation 
of activated immune cells [43]. Further analysis revealed 
that COX inhibitors and EP4 receptor antagonism con-
tribute to NK functions critical to the control of meta-
static disease. In vivo, NK cells were necessary for the 
therapeutic effects of COX inhibitors. Further, mammary 
tumor cells treated with COX inhibitors were more sensi-
tive to NK mediated lysis. Moreover, expression of inhib-
itory ligands for NK cells were decreased and stimulatory 
ligands were increased by treatment with COX inhibitors 
or EP4 receptor antagonists. These studies suggest that 
EP4, expressed on malignant cells, is a potential thera-
peutic target [26, 44, 45].
COX-2 inhibition would cause the loss of the M2 mac-
rophage characteristics of TAMs and may assist preven-
tion of breast cancer metastasis. Chen et al. [46] suggest 
that inhibition of myeloid cell COX-2 can potentiate 
CTL-mediated tumor cytotoxicity and may provide a 
novel therapeutic approach in breast cancer therapy. 
They found that the specific COX-2 inhibitor, inhibited 
human M2 macrophage differentiation, as determined by 
decreased CD14 and CD163 expressions and increased 
TNFγ production. At the same time, COX-2 inhibition 
alters the phenotype of tumor-associated macrophages 
from M2 to M1 in ApcMin/+ mouse polyps.
Meanwhile, COX-2 inhibition potentiates mac-
rophage’s inflammatory cytokine responses but reduces 
IL-10 secretion thus might skew overall tumor micro-
environment to favor Th1 immune responses which 
was confirmed by reduced regulatory T cells as well as 
myeloid derived suppressor cells in etodolac fed mice 
tumor mass [45]. COX-2 KO mice resulted from dis-
ruption of M2-like TAM function, and thereby enhanc-
ing T cell survival and immune surveillance [46]. 
PGE2 seems to influence the antigen-specific cellular 
responses of both T cells and APCs because reversal 
of inhibition was seen by pretreatment of both with 
COX-2 inhibitor. COX-2 inhibitor attenuates Treg cell 
activity and Foxp3 expression in tumor-infiltrating lym-
phocytes and enhances antitumor responses [47, 48], 
which still delays primary tumor growth and reduces 
MDSC accumulation [49].
Meta-analysis of independent estimates from 72 studies 
provides no evidence that the selective COX-2 inhibitor 
will influence the relative risk of cardiovascular disease 
(composite relative risk  =  0.98, 95  % CI  =  0.88–1.10) 
[50]. Meanwhile, the mechanisms of COX-2 inhibitors 
regulate the tumor immune evasion still needs further 
research.
Conclusion
In this review, we have tried to encompass the role of 
COX-2 in the regulation of tumor immune evasion. The 
activity of COX-2 is suspected to promote angiogenesis, 
tissue invasion of tumors and resistance to apoptosis and 
chemotherapy. The activity of COX-2-PGE2-Prostaglan-
din E Receptors signal pathway can suppress Dendritic 
cells (DCs), natural killer (NK), T cells, type-1 immunity, 
but promote type-2 immunity, which promote tumor 
immune evasion. COX-2 and the prostaglandin cas-
cade play an important part in the “inflammogenesis of 
cancer”. In addition, COX-inhibitors can inhibit tumor 
immune evasion. Therefore, we can exert the COX-inhib-
itors benefit from addition of COX-inhibitors to standard 
cytotoxic therapy, which can overcome tumor immune 
evasion.
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